Skip to content
‹ Back to IndustriesSciences

Fiberguide Gears Up for the UK’s Premiere Event for Photonics and Light Technologies

f you’re involved in photonics, fiber optics, or other advanced light technologies, you know what a challenge it is to keep up with this rapidly changing industry that’s growing every year. That’s why it’s essential to attend PHOTONEX EUROPE LIVE! Photonex attendees represent every part of the supply chain including suppliers, consultants, industrial users, researchers,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · · Fiberguide ArticlePromoted Content
Share
Fiberguide Gears Up for the UK’s Premiere Event for Photonics and Light Technologies

Key takeaways

01

f you’re involved in photonics, fiber optics, or other advanced light technologies, you know what a challenge it is to keep up with this rapidly changing industry that’s growing every year.

02

That’s why it’s essential to attend PHOTONEX EUROPE LIVE!

03

Photonex attendees represent every part of the supply chain including suppliers, consultants, industrial users, researchers,…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

f you’re involved in photonics, fiber optics, or other advanced light technologies, you know what a challenge it is to keep up with this rapidly changing industry that’s growing every year. That’s why it’s essential to attend PHOTONEX EUROPE LIVE! Photonex attendees represent every part of the supply chain including suppliers, consultants, industrial users, researchers, scientists, and innovative newcomers. That’s why Fiberguide is excited to be attending Photonex as an exhibitor.

PHOTONEX EUROPE LIVE! is a Great Place to Network

Ricoh Arena in Coventry, UK will host Photonex on October 10th and 11th. This exciting and allows attendees to get a first look at ground-breaking technology, innovative solutions, and the latest industry trends, all at no charge. Photonex provides key players in the photonics industry the opportunity to network face-to-face and share valuable information. The free conference also offers educational sessions and expert-led presentations and discussions. Further, attendees can interact with exhibitors to examine, handle, compare, and test-drive the latest products and technologies.

Come See Fiberguide in the Exhibition Hall

Fiberguide will be attending Photonex as an exhibitor at Booth C14 to promote their fibers for photonics applications, including their RARe Motheye Fiber. This patented fiber is the result of a unique process which creates randomized nanostructures on the fiber surface. This results in fiber optic cables with improved anti-reflective properties, extreme durability, and high efficiency when compared with those made with the non-randomized processes commonly used in AR coatings. Fiberguide’s cutting-edge RARe Motheye Fiber is engineered from nature to bring colossal and revolutionary bandwidth and superior wavelength range when compared with coated thin-film surfaces.

Fiberguide is an Industry Leader in Fiber Optics

Fiberguide delivers efficient, cost-effective, practical fiber optic solutions engineered to meet the unique needs of our customers across the globe. For more than three decades, Fiberguide Industries has been a reliable, long-term, strategic partner with OEM manufacturers, providing large core specialty optical fiber, high temperature metalized optical fibers, and packaged fibers in a variety of assemblies and bundles for optical power delivery and optical sensing applications. Visit Fiberguide at PHOTONEX EUROPE LIVE! at Booth C14 to see our innovative products firsthand.

Read more at fiberguide.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

PC
Promoted Content
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512